nesiritide + dobutamine

**Nesiritide + dobutamine** is a combination of two intravenous drugs used as vasoactive agents in the management of **acutely decompensated congestive heart failure (CHF)**. Nesiritide is a recombinant form of human B-type natriuretic peptide and acts as a natriuretic/vasodilator hormone, while dobutamine is a catecholamine and acts as a β1-adrenergic receptor agonist (inotrope)[1][2]. This combination may be co-administered in clinical settings where dual action—vasodilation, natriuresis, and increased cardiac contractility—is required for acute heart failure with significant hemodynamic compromise. Both improve symptoms of CHF, but dobutamine is associated with higher rates of arrhythmias and tachycardia[1], while nesiritide tends to reduce ventricular ectopy or have a neutral effect[1].